Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials

Journal of Clinical Pharmacology

Volumn 49, Issue 9, 2009, Pages 1012-1024

  Wang, Diane D ^a,c   Shuzhong Zhang, ^a   Hong Zhao, ^b   Men, Angela Y ^b   Parivar, Kourosh ^a  

^a PFIZER INC   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NONE   (United States)

Author keywords

Biologics; Body size based dosing; Body surface area; Body weight; Fixed dosing; Monoclonal antibodies; Pharmacodynamics; Population pharmacokinetics

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CETUXIMAB; EFALIZUMAB; GOLIMUMAB; INFLIXIMAB; MATUZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PERTUZUMAB; RITUXIMAB; SIBROTUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY SIZE; BODY SURFACE; BODY WEIGHT; CLINICAL PRACTICE; CONTROLLED STUDY; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; RECOMMENDED DRUG DOSE;

ADULT; ANTIBODIES, MONOCLONAL; BODY SURFACE AREA; BODY WEIGHT; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL;

EID: 69549118367     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009337512     Document Type: Article

References (30)

1. Sawyer M., Ratain MJ Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001 ; 19 (2). 171-177.
2. Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J., Sparreboom A. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference ? Oncologist. 2007 ; 12 (8). 913-923.
3. Belle DJ, Singh H. Genetic factors in drug metabolism. Am Fam Physician. 2008 ; 77 (11). 1553-1560.
4. Shu Y., Brown C., Castro RA, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 2008 ; 83 (2). 273-280.
5. Scripture CD, Figg WD Drug interactions in cancer therapy. Nat Rev Cancer. 2006 ; 6 (7). 546-558.
6. Dobbs NA, Twelves CJ What is the effect of adjusting epirubicin doses for body surface area ? Br J Cancer. 1998 ; 78 (5). 662-666.
7. Gurney HP, Ackland S., Gebski V., Farrell G. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol. 1998 ; 16 (7). 2299-2304.
8. Piotrovsky VK, Huang ML, Van Peer A., Langenaecken C. Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients. Cancer Chemother Pharmacol. 1998 ; 42 (3). 221-228.
9. Ratain MJ, Mick R., Schilsky RL, Vogelzang NJ, Berezin F. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol. 1991 ; 9 (8). 1480-1486.
10. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996 ; 14 (9). 2590-2611.
11. Baker SD, Verweij J., Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst. 2002 ; 94 (24). 1883-1888.
12. Mathijssen RH, Verweij J., de Jonge MJ, Nooter K., Stoter G., Sparreboom A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol. 2002 ; 20 (1). 81-87.
13. Lobo ED, Hansen RJ, Balthasar JP Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004 ; 93 (11). 2645-2668.
14. Guru V., Fremes S., Tu J. How do gender, body surface area (BSA) and body mass index (BMI) impact on mortality of patients undergoing isolated coronary artery bypass graft (CABG) surgery in Ontario 57th Annual Meeting of Canadian Cardiovascular. Congress. 2004 ; 47 (3). 383-396.
15. Hermanussen M., Danker-Hopfe H., Weber GW Body weight and the shape of the natural distribution of weight, in very large samples of German, Austrian and Norwegian conscripts. Int J Obes Relat Metab Disord. 2001 ; 25 (10). 1550-1553.
16. Hayashi N., Tsukamoto Y., Sallas WM, Lowe PJ A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol. 2007 ; 63 (5). 548-561.
17. Mrozek K., Marcucci G., Paschka P., Whitman SP, Bloomfield CD Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification ? Blood. 2007 ; 109 (2). 431-448.
18. Yang CH, Yu CJ, Shih JY, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol. 2008 ; 26 (16). 2745-2753.
19. Goncalves A., Esteyries S., Taylor-Smedra B., et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer. 2008 ; 8: 169.
20. Ng CM, Bruno R., Combs D., Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005 ; 45 (7). 792-801.
21. Sun YN, Lu JF, Joshi A., Compton P., Kwon P., Bruno RA Population pharmacokinetics of efalizumab humanized monoclonal anti- CD11a antibody following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol. 2005 ; 45 (4). 468-476.
22. Ng CM, Lum BL, Gimenez V., Kelsey S., Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res. 2006 ; 23 (6). 1275-1284.
23. Lu JF, Bruno R., Eppler S., Novotny W., Lum B., Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008 ; 62: 779-786.
24. Kuester K., Kovar A., Lupfert C., Brockhaus B., Kloft C. Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development. Br J Cancer. 2008 ; 98 (5). 900-906.
25. Kloft C., Graefe EU, Tanswell P., et al. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Invest New Drugs. 2004 ; 22 (1). 39-52.
26. Dirks NL, Nolting A., Kovar A., Meibohm B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol. 2008 ; 48 (3). 267-278.
27. Zhou H., Jang H., Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007 ; 47 (3). 383-396.
28. Xu Z., Seitz K., Fasanmade A., et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol. 2008 ; 48 (6). 681-695.
29. Bruno R., Washington CB, Lu JF, Lieberman G., Banken L., Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2005 ; 56 (4). 361-369.
30. Bonate PL, Keating M., Weitman S., Hillmen P., Mould DR Population pharmacokinetics of alemtuzumab in patients with hematologic malignancies. Paper presented at: 47th Annual Meeting of the American Society of Hematology ; December 10-13, 2005 ; Atlanta, Georgia.